key: cord-0950663-k1rw23nz authors: Yadav, Pragya; Mohandas, Sreelekshmy; Sarkale, Prasad; Nyayanit, Dimpal; Shete, Anita; Sahay, Rima; Potdar, Varsha; Baradkar, Shreekant; Gupta, Nivedita; Sapkal, Gajanan; Abraham, Priya; Panda, Samiran; Bhargava, Balram title: Isolation of SARS-CoV-2 B.1.1.28.2 P2 variant and pathogenicity comparison with D614G variant in hamster model date: 2021-05-24 journal: bioRxiv DOI: 10.1101/2021.05.24.445424 sha: d39df61c2f9e01c64c5ad087c3a6b8779979194d doc_id: 950663 cord_uid: k1rw23nz Background Considering the potential threat from emerging SARS-CoV-2 variants and the rising COVID-19 cases, SARS-CoV-2 genomic surveillance is ongoing in India. We report herewith the isolation of the P.2 variant (B.1.1.28.2) from international travelers and further its pathogenicity evaluation and comparison with D614G variant (B.1) in hamster model. Methods Virus isolation was performed in Vero CCL81 cells and genomic characterization by next generation sequencing. The pathogenicity of the isolate was assessed in Syrian hamster model and compared with B.1 variant. Results B.1.1.28.2 variant was isolated from nasal/throat swabs of international travelers returned to India from United Kingdom and Brazil. The B.1.1.28.2 variant induced body weight loss, viral replication in the respiratory tract, lung lesions and caused severe lung pathology in infected Syrian hamster model in comparison, with B.1 variant infected hamsters. The sera from B.1.1.28.2 infected hamsters efficiently neutralized the D614G variant virus whereas 6-fold reduction in the neutralization was seen in case of D614G variant infected hamsters’ sera with the B.1.1.28.2 variant. Conclusions B.1.1.28.2 lineage variant could be successfully isolated and characterization could be performed. Pathogenicity of the isolate was demonstrated in Syrian hamster model and in comparison, with B.1 variant was found more pathogenic. The findings of increased disease severity and neutralization reduction is of great concern and point towards the need for screening the vaccines for efficacy. Over the year of COVID-19 pandemic, Severe Acute Respiratory Syndrome Corona virus-2 (SARS-CoV-2) has accumulated severe mutations leading to the emergence of new variants. The first SARS-CoV-2 variant of concern, B.1.1.7, 20I/501Y.V1, VOC202012/01 was identified in late December in the United Kingdom (UK) which is now reported in more than 62 countries in Europe, Asia, United States of America, and elsewhere. This variant has about 17 mutations, including N501Y, P681H, 69-70 deletion; the ORF8 Q27stop mutation outside the spike protein and is adapted to be more transmissible [1] . Subsequently, another variant B.1.351, 20C/501Y.V2 was identified in South Africa with 21 mutations, including N501Y, E484K, and K417N on the spike protein, and ORF1b deletion outside the spike protein. It has been reported in Africa, Europe, Asia, and Australia with studies reporting potential immune escape [2] . During January 2021, lineage P.1, also known as 20J/501Y.V3, Variant of Concern with 17 amino acid changes which includes N501Y, E484K, and K417N on the spike protein; ORF1b deletion outside the spike protein was determined in the travelers from Brazil at Japan. The virus has been found to be widely distributed in Amazonas state of Brazil and also noticed in the Faroe Islands, South Korea, and USA [3, 4] . The virulence, transmissibility and immune invasion potential of this variant remains unknown. Still, there is a concern that this variant might have facilitated the re-infections in Manus city of Amazonas which had achieved herd immunity in October 2020. Furthermore, Brazil reported another variant P.2 lineage, which has E484K mutation but not the N501Y and K417N amino acid changes in the spike protein [3] . Public health experts across the globe are rigorously following the three most rampantly spreading SARS-CoV-2 variants identified in the United Kingdom, South Africa and Brazil with concern. The mutations in receptor binding domain (RBD) of the spike protein enabled these variants to have strong affinity and binding capacity to receptor Angiotensin converting enzyme 2 (ACE2) leading to higher transmissibility [1] [2] [3] [4] .Also, many of these variants are reported to be linked to the immune escape and neutralization reduction threatening the vaccine policies and potential monoclonal antibody treatments [5, 6] . Pathogenicity of the SARS-CoV-2 virus variants can be assessed in animal models. For SARS CoV-2 multiple animal models are available like ferrets, Syrian hamsters, non-human primates etc [7] . Among this, Syrian hamster is a widely used model for SARS CoV-2 which develops pneumonia and body weight loss following infection (Mohandas et al., 2020) .Syrian hamsters have been used to assess the pathogenicity of many SARS-CoV-2 variants like B.1, B.1.1.7, B.1.617 [8, 9] . In India, many cases of UK variants have been already reported [10] [12] . Increase in the COVID-19 cases has been observed during the early 2021. Considering the potential threat from emerging variants, the Government of India has continued the SARS-CoV-2 genomic surveillance of the International travelers and their contact tracing. Here, we report isolation and characterization of the Brazil P.2 (B.1.1.28.2) lineage from clinical specimens of international travelers and its impact on hamster while infected and compared with B.1 variant with known mutation of D614G. The throat/nasal swabs of two COVID-19 asymptomatic cases (aged 69 and 26 years) were used for the isolation. The samples were of international travelers who returned from UK (in December 2020) and Brazil (in January 2021) respectively to India. Both the cases did not have any co-morbid conditions and were asymptomatic throughout the course of infection till recovery. Hundred microliters of the tissue homogenate/ swab specimens were added onto a 24-well plate of VeroCCL81 cells and incubated at 37°C for one hour. After washing with phosphate buffered saline and removal of media, the plates were incubated with maintenance media in a CO2 incubator at 37°C. The plates were observed daily for any cytopathic effects (CPE) using an inverted microscope (Nikon, Eclipse Ti, Japan). On observation of CPE, the supernatant was harvested and confirmed by real-time RT-PCR. Titration was performed by Reed and Muench method and titer was expressed as TCID50/ml [14] . Genomic characterization of clinical samples and virus isolates were carried out using Next-Generation Sequencing (NGS) as per earlier explained protocols [15] . Briefly, ribosomal RNA depletion was carried on the extracted RNA using Nebnext rRNA depletion kit (Human/mouse/rat) (New England BioLabs. In, USA). Subsequently, cDNA was synthesized with the first strand and second synthesis kit. The RNA libraries were prepared using TruSeqStranded total RNA library preparation kit (Illumina, USA). The amplified RNA libraries were quantified and loaded on the MiSeq Illumina sequencing platform after normalization [6] . The genomic sequences for the clinical specimens and the virus isolates were retrieved using the reference-based mapping with the SARS-CoV-2 reference sequence (Accession Number: NC_045512.2) in CLC Genomics Workbench v20.0.4 and submitted to the public repository i.e., GISAID. The retrieved sequences were aligned with other representative SARSCoV-2 sequences downloaded from the GISAID database and a phylogenetic tree was generated with representative sequences from GISAID. General Time Reversible model with Gamma distribution of 0.05 and a boot strap replication of 1000 cycles was used to generate a Maximum-Likelihood tree. All the animal experiments were performed with the approval of Institutional Animal Ethics Committee and as per the guidelines of CPCSEA, India. To understand the pathogenicity of the isolate, we intranasally inoculated 10 4 TCID50 virus dose of Brazil P.2 (B.1.1.28.2) in 9 Syrian hamsters and observed them for 7 days for any disease and three hamsters from each group were sacrificed on day 3, 5 and 7 to study the organ viral load, antibody response and lung pathology. Simultaneously the pathogenicity of this variant was Nasal wash, throat swab and organ tissue samples were collected from hamsters at necropsy. Organ samples were homogenized in 1 ml cell culture media using tissue homogenizer (Eppendorf, Germany). MagMAX™ Viral/Pathogen Nucleic Acid Isolation Kit was used for RNA extraction as per the manufacturer's instructions. Real-time RT-PCR was performed for SARS-CoV-2 E gene (both genomic and subgenomic RNA) as described earlier [16, 17] . The hamster serum samples collected on day 3, 5, 7 post virus inoculation were tested for IgG antibodies by hamster anti-SARS-CoV-2 IgG ELISA as described earlier [18] . PRNT50 was performed on serum samples of hamsters against SARS-CoV-2 B.1 variant and B.1.1.28.2 variant as per earlier described methodology [19] . Lungs samples fixed in 10% neutral buffered formalin were processed using an automated tissue processor and were embedded in paraffin. The tissues were sectioned using an automated microtome (Leica, Germany) and stained by routine hematoxylin and eosin staining. The lesions were graded as severe (+4), moderately severe (+3), minimal (+2), mild (+1) and no lesions (0) after scoring for the vascular changes, alveolar damage and inflammatory changes. Graph pad Prism version 8.4.3 software was used for the analysis. Non parametric Mann Whitney tests were used and the p-values less than 0.05 were considered to be statistically significant. he he dy in hamsters were -9%, -15% and -20% on day 3, 5 and 7 respectively (Figure 2A ). Viral genomic RNA load was highest on day 3 and among the organs, lungs (mean = 2.7 x 10 11 copies/ml) showed the maximum viral RNA load followed by trachea (mean= 5.9 x 10 8 copies/ml and nasal turbinate's(mean = 3.2 x 10 9 copies/ml).Nasal wash and throat swab showed mean gRNA load of 1.6 x 10 9 and 3.3 x 10 8 copies/ml ( Figure 2B-F Table 1 ).The increased pathogenicity of the B.1.1.28.2 variant isolate as evident by the increased body weight loss, high viral load in lungs and severe lung pathology. The unpredictable. This also emphasizes for the specific precautions for the isolation and the management of these cases. Here we assessed the pathogenicity of the isolate and observed disease in hamster model characterized by the weight loss and lung pneumonic changes. COVID-19 in hamsters is characterized by respiratory signs, body weight loss and pneumonia [20] . Hamster model has been used to assess the infectivity and pathogenicity of SARS-CoV-2 VOCs like B.1.1.7, B.1.351, B.1.617etc [18, 21] . The variant specific differences can be evaluated with this model using criteria's like viral load, histological scoring, inflammatory cytokine level etc [18, 21] . Hence genomic surveillance of SARS-CoV-2 would help in early identification of the variants of concern specifically when it is present at a low frequency. This would help in implementation of various control measures to curb the transmission of SARS-CoV-2 variants in the country. It would also allow quick assessment of their prevalence across the globe. With the research underway to determine the neutralization potential of currently available COVID-19 vaccine, we still need to continue to follow the non-pharmaceutical interventions such as use of masks, physical distancing, hand hygiene and avoiding the public gatherings which would check the transmission of these new variants to a great extent. Here we report the isolation of the B. to understand its pathogenicity and immune escape potential for preparedness. Investigation of novel SARS-CoV-2 variant: variant of concern 202012/01, technical briefing 3. London, United Kingdom: Public Health England Emergence and rapid spread of a new severe acute respiratory syndrome-related coronavirus 2 (SARS267 CoV-2) lineage with multiple spike mutations in South Africa Genomics and epidemiology of the P.1 SARS-CoV-2 lineage in Manaus Emerging SARS-CoV-2 Variants Neutralization of variant under investigation B. 1.617 with sera of BBV152 vaccinees Multiple SARS-CoV-2 variants escape neutralization by vaccine-induced humoral immunity Animal models for COVID-19 Comparison of the pathogenicity and virus shedding of SARS CoV-2 VOC 202012/01 and D614G variant in hamster model SARS CoV-2 variant B. 1.617. 1 is highly pathogenic in hamsters than B. 1 variant. bioRxiv Isolation and characterization of the new SARS-CoV-2 variant in travellers from the United Kingdom to India: VUI-202012/01 of the B. 1.1. 7 lineages Imported SARS-CoV-2 V501Y.V2 variant (B.1.351) detected in travelers from South Africa and Tanzania to India Convergent evolution of SARS-CoV-2 spike mutations, L452R, E484Q and P681R, in the second wave of COVID-19 in First isolation of SARS-CoV-2 from clinical samples in India A simple method of estimating fifty per cent endpoints Genome Sequencing of Kaisodi Virus Isolated from Ticks in India Belonging to Phlebovirus Genus, Family Phenuiviridae Development of in vitro transcribed RNA as positive control for laboratory diagnosis of SARS-CoV-2 in India Virological assessment of hospitalized patients with COVID-2019 Immunogenicity and protective efficacy of BBV152, whole virion inactivated SARS-CoV-2 vaccine candidates in the Syrian hamster model Neutralizing antibody responses to SARS-CoV-2 in COVID-19 patients Evaluation of the susceptibility of mice & hamsters to SARS-CoV-2 infection Comparative infectivity and pathogenesis of emerging SARS-CoV-2 variants in Syrian hamsters Subtle differences in the pathogenicity of SARS-CoV-2 variants of concern B. 1.1. 7 and B. 1.351 in rhesus macaques SARS-CoV-2 variant classifications and definitions Neutralization of B.1.1.28 P2 variant with sera of natural SARS-CoV-2 infection and recipients of BBV152 vaccine We gratefully acknowledge the team member of Maximum Containment Facility, ICMR-NIV, No conflict of interest exists among authors.